Search

Your search keyword '"Schwäble, Joachim"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Schwäble, Joachim" Remove constraint Author: "Schwäble, Joachim"
46 results on '"Schwäble, Joachim"'

Search Results

2. Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation.

3. Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care units

4. Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

5. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients

6. First human leucocyte antigen (HLA) response and safety evaluation of fibrous demineralized bone matrix in a critical size femoral defect model of the Sprague Dawley rat

8. First Human Leucocyte Antigen (HLA) Response and Safety Evaluation of Fibrous Demineralized Bone Matrix in a Critical Size Femoral Defect Model of the Sprague-Dawley Rat

10. Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B

12. Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions

13. High efficiency gene correction in hematopoietic cells by donor-template-free CRISPR/Cas9 genome editing

15. Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions

16. Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing

17. CD133-targeted Gene Transfer Into Long-term Repopulating Hematopoietic Stem Cells

18. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

19. From bench to bedside : preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease

20. Gentherapie der septischen Granulomatose : Chancen und Risiken ; der Weg zur erfolgreichen Therapie einer angeborenen Immundefizienz

21. From Bench to Bedside: Preclinical Evaluation of a Self-Inactivating Gammaretroviral Vector for the Gene Therapy of X-linked Chronic Granulomatous Disease

22. Alpharetroviral Vector-mediated Gene Therapy for X-CGD: Functional Correction and Lack of Aberrant Splicing

25. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

27. Flt3-dependent transformation by inactivating c-Cbl mutations in AML

28. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors

29. Wnt signaling regulates transendothelial migration of monocytes

31. Constitutive Activation of Akt by Flt3 Internal Tandem Duplications Is Necessary for Increased Survival, Proliferation, and Myeloid Transformation

34. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation

35. Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non–Small Cell Lung Cancer

36. High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets

37. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

38. The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARaand regulates differentiation of hematopoietic cells.

39. RGS2is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation

43. Selective red blood cell depletion by apheresis in sheep causes severe normovolemic anemia.

44. High Efficiency Gene Correction in Hematopoietic Cells by Donor-Template-Free CRISPR/Cas9 Genome Editing.

46. Flt3 receptor tyrosine kinase as a drug target in leukemia.

Catalog

Books, media, physical & digital resources